o2h

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

Atelerix Limited, based in Cambridge, United Kingdom, specializes in the storage and transportation of viable cells and tissues at room temperature. Founded in 2006, the company has developed a patented technology that utilizes alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipping. This innovative approach eliminates the need for cryopreservation, making it easier for customers to use cells and assays immediately upon arrival without the risk of cytotoxicity or damage. Atelerix's technology enhances predictability and reliability in drug discovery models and cell therapies, allowing for the safe storage and transport of suspended and planted cells, as well as tissues and stem cells.

Healx is a biotechnology company specializing in the development of treatments for rare diseases through the use of generative artificial intelligence. By employing advanced AI and machine learning technologies, Healx focuses on identifying potential drug candidates and repurposing existing medications for new therapeutic applications. This approach takes advantage of the established safety profiles of known drugs, thereby minimizing the risks and costs typically associated with creating new pharmaceuticals from scratch. Through its innovative platform, Healx aims to accelerate the development of novel treatments, addressing the unmet medical needs of patients suffering from rare diseases worldwide.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

Pencil Biosciences is focused on creating an innovative genome modulation platform that addresses the limitations of existing gene-editing technologies. By developing a programmable tool for genome modulation, the company aims to provide new therapeutic options for patients suffering from rare diseases. This technology is designed to have a broad impact, allowing medical professionals to navigate the complexities of gene editing more effectively. Through its advancements, Pencil Biosciences seeks to enhance the capabilities of gene-editing applications in the medical field.

Kuano Ltd specializes in developing quantum and AI solutions aimed at molecular design, particularly in the fields of drug discovery and development. Founded in 2020 and based in London, the company integrates quantum simulation with machine learning to create effective enzyme inhibitors. Its innovative discovery platform employs target quantum mapping alongside AI-driven chemistry, facilitating the faster and more efficient development of superior drug candidates. Kuano's technology is applicable across several sectors, including pharmaceuticals, crop protection, and industrial chemistry, ultimately enhancing the quality of new therapeutics while reducing the time required for their discovery.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that was incorporated in 2016. The company specializes in using medicinal chemistry and artificial intelligence to design small molecule drugs. PharmEnable has developed a rapid and cost-effective method for identifying improved chemical starting points, which aims to enhance the discovery of essential new medicines.

Five Alarm Bio Ltd. is a drug discovery company founded in 2016 and based in Cambridge, United Kingdom. The company focuses on researching and developing anti-aging therapies aimed at addressing various age-related diseases and limitations. By employing a small molecule strategy, Five Alarm Bio seeks to enhance the body's natural defenses against aging-related damage. Its goal is to create innovative therapeutics that can extend the lifespan of healthy cells and mitigate the onset and progression of aging-related conditions.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in manufacturing high-purity, animal-free growth factors, cytokines, and complex proteins. The company leverages proprietary protein production processes developed at the University of Cambridge, along with advanced protein engineering techniques, to create unique products that address key challenges in the stem cell, organoid, regenerative medicine, and cultivated meat sectors. Qkine's product line includes innovative offerings such as tag-free thermostable FGF-2, the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF. With an active research and development pipeline and a commitment to quality, Qkine is ISO 9001:2015 certified, ensuring that it provides high-purity, bioactive proteins to support scientific advancements in life sciences.

Operator of a biotechnology company intended to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company aims for therapeutic applications in diseases with high unmet clinical needs such as fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), liver and kidney disease and cancer, enabling patients affected by life-limiting conditions to access effective treatments and relief.

CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Neurocentrx is a company dedicated to developing oral delivery medicines aimed at treating patients with neurological conditions, including psychiatric and mood disorders, neurodegenerative diseases, and complex pain management related to cancer and palliative care. By focusing on existing approved drugs, Neurocentrx seeks to enhance patient outcomes through reformulation, reindication, clinical development, and product in-licensing. Their innovative approach includes the development of oral ketamine formulations that specifically target central nervous system conditions and alleviate severe and chronic neuropathic pain, thereby improving the quality of life for patients suffering from these debilitating conditions.

Xploro is a health information platform focused on empowering young patients through innovative technology. The company has developed a mobile application that combines augmented reality, gameplay, and artificial intelligence to provide health information in an engaging and informative manner. By making the learning process enjoyable, Xploro aims to reduce stress and anxiety among young patients, ultimately enhancing their clinical outcomes. The platform is clinically validated and recognized for its effectiveness in delivering patient education tailored to the needs of children, ensuring they feel both informed and empowered in their healthcare journeys.

Neuroute is an AI-driven platform that enhances the efficiency of clinical trials by optimizing patient recruitment. It offers a web-based solution that empowers healthcare professionals to connect with patients and streamline clinical development processes. By utilizing artificial intelligence, Neuroute generates targeted patient recruitment strategies and campaigns, which aim to improve outcomes for both patients and clinical innovators. The company is supported by prominent pharmaceutical firms, including Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche, and Eli Lilly, highlighting its credibility and commitment to advancing healthcare.

Neuroute is an AI-driven platform that enhances the efficiency of clinical trials by optimizing patient recruitment. It offers a web-based solution that empowers healthcare professionals to connect with patients and streamline clinical development processes. By utilizing artificial intelligence, Neuroute generates targeted patient recruitment strategies and campaigns, which aim to improve outcomes for both patients and clinical innovators. The company is supported by prominent pharmaceutical firms, including Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche, and Eli Lilly, highlighting its credibility and commitment to advancing healthcare.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

AI VIVO operates an AI-based proprietary pharmacology platform focused on capturing the dynamic effects of diseases and treatments at the organ level. This innovative approach enhances drug discovery and development by utilizing organ-level models to improve the clinical predictability of new therapies. The platform transforms biological hypotheses into data representation, allowing for the translation of this data into meaningful medical insights. As a result, AI VIVO provides the healthcare industry with advanced methodologies that facilitate novel discoveries and improve treatment outcomes.

Sanome is focused on addressing the growing demand for healthcare services by enhancing early detection and prevention strategies. The company has developed a predictive analytics tool that aids clinicians in identifying patient health changes earlier, thereby improving decision-making in clinical settings. By integrating healthcare data with advanced artificial intelligence and biophysical biomarkers, including at-home composite tests, Sanome's platform provides actionable clinical insights. This approach enables healthcare providers to detect potential health issues before they escalate, ultimately leading to better patient outcomes and increased operational efficiency. The company's long-term vision includes creating a human digital twin that continuously monitors individual health, informing clinicians about significant changes through its Clinical Co-pilot.

BiVictriX Therapeutics Ltd. is a UK-based company focused on drug discovery and development, specializing in bispecific antibody drug conjugates aimed at addressing unmet needs in blood cancer treatment. Established in 2016 and located in Alderley Edge, the company employs its proprietary Bi-Cygni technology to create innovative therapeutics, particularly for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX's expertise encompasses oncology, hematological malignancies, immunotherapy, and antibody research, positioning it as a key player in the development of advanced biotherapeutics and drug development initiatives.

Kuano Ltd specializes in developing quantum and AI solutions aimed at molecular design, particularly in the fields of drug discovery and development. Founded in 2020 and based in London, the company integrates quantum simulation with machine learning to create effective enzyme inhibitors. Its innovative discovery platform employs target quantum mapping alongside AI-driven chemistry, facilitating the faster and more efficient development of superior drug candidates. Kuano's technology is applicable across several sectors, including pharmaceuticals, crop protection, and industrial chemistry, ultimately enhancing the quality of new therapeutics while reducing the time required for their discovery.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

Stingray Bio is a biotechnology company focused on developing precision therapeutics for cancer treatment, specifically targeting the LMTK3 kinase. The company utilizes its expertise in structural biology, cellular biology, and cancer pharmacology to create innovative cancer agents aimed at treating conditions such as breast cancer. By concentrating on the LMTK3 kinase, Stingray Bio aims to support healthcare providers and drug developers in delivering novel treatments to patients, ultimately advancing the field of oncological therapeutics.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

Turbine Ltd is a biotechnology company based in Budapest, Hungary, founded in 2015. It specializes in the development of computational models that predict biological and clinical outcomes to aid in cancer drug development. Utilizing its proprietary Simulated Cell technology alongside artificial intelligence, Turbine focuses on understanding the intricate mechanisms of cancer. This approach facilitates the discovery of novel protein targets and precision biomarkers, enhancing the translation of research to patient care. The company also creates cancer combination therapies that clarify the underlying biology of diseases and personalize treatment options. By leveraging bioinformatics and network medicine, Turbine effectively simulates complex interventions, allowing for the screening of numerous drug combinations on simulated cells. This innovative process aims to provide cancer patients with low-cost and effective treatment plans.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

Privitar Ltd. is an enterprise software company specializing in privacy-preserving data mining and advanced data anonymization solutions. Founded in 2014 and headquartered in London, the company serves a diverse global client base across North America, Europe, and Asia. Privitar's product suite includes Privitar Publisher, which allows organizations to securely manage and audit data access, and Privitar Lens, which facilitates the creation of privacy-preserving APIs for reporting and analytics. Additionally, its SecureLink system focuses on data de-identification, while the Privitar Data Privacy Platform enhances data utilization while safeguarding sensitive information. The company's technologies enable clients to analyze potentially sensitive data in compliance with regulations such as GDPR, CPRA, and HIPAA, thereby fostering data-driven innovation and maintaining customer privacy across various sectors, including finance, healthcare, telecommunications, and marketing.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in manufacturing high-purity, animal-free growth factors, cytokines, and complex proteins. The company leverages proprietary protein production processes developed at the University of Cambridge, along with advanced protein engineering techniques, to create unique products that address key challenges in the stem cell, organoid, regenerative medicine, and cultivated meat sectors. Qkine's product line includes innovative offerings such as tag-free thermostable FGF-2, the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF. With an active research and development pipeline and a commitment to quality, Qkine is ISO 9001:2015 certified, ensuring that it provides high-purity, bioactive proteins to support scientific advancements in life sciences.

Pencil Biosciences is focused on creating an innovative genome modulation platform that addresses the limitations of existing gene-editing technologies. By developing a programmable tool for genome modulation, the company aims to provide new therapeutic options for patients suffering from rare diseases. This technology is designed to have a broad impact, allowing medical professionals to navigate the complexities of gene editing more effectively. Through its advancements, Pencil Biosciences seeks to enhance the capabilities of gene-editing applications in the medical field.

Neurofenix is focused on enhancing rehabilitation for stroke survivors by developing an innovative upper limb rehabilitation device. This device features a hand-training controller that allows users to engage in video games, making the rehabilitation process both enjoyable and effective. By enabling patients to perform arm and hand exercises in both clinical settings and at home, Neurofenix aims to provide more autonomous and accessible therapy solutions for individuals recovering from strokes.

Turbine Ltd is a biotechnology company based in Budapest, Hungary, founded in 2015. It specializes in the development of computational models that predict biological and clinical outcomes to aid in cancer drug development. Utilizing its proprietary Simulated Cell technology alongside artificial intelligence, Turbine focuses on understanding the intricate mechanisms of cancer. This approach facilitates the discovery of novel protein targets and precision biomarkers, enhancing the translation of research to patient care. The company also creates cancer combination therapies that clarify the underlying biology of diseases and personalize treatment options. By leveraging bioinformatics and network medicine, Turbine effectively simulates complex interventions, allowing for the screening of numerous drug combinations on simulated cells. This innovative process aims to provide cancer patients with low-cost and effective treatment plans.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Small Pharma Ltd. is a pharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, utilizing expert teams to design and execute development programs. This approach leverages academic discoveries and focuses on effective intellectual property design, ensuring that the various disciplines essential for successful drug development are addressed by qualified professionals.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

DeepMatter Group Plc is a big data and analysis company based in Bristol, United Kingdom. The company operates through two segments: DeepMatter and InfoChem. It has developed the DigitalGlassware platform, which enhances reproducibility in chemistry by delivering applications that optimize chemicals, materials, and formulations in key areas such as pharmaceutical research, fine chemicals, and scientific education. DeepMatter also focuses on cheminformatics software that manages, stores, and retrieves chemical structures and reactions, facilitating synthesis planning and reaction prediction. Additionally, the company engages in the automatic extraction of scientific information from texts and images, contributing to the digitization of chemical space and discovery. Formerly known as Cronin Group Plc, the company rebranded in May 2018 and has been operational since its incorporation in 2006.

Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.

Oppilotech Ltd, founded in 2014 and based in London, United Kingdom, specializes in the development of antibacterial compounds aimed at combating drug-resistant organisms. The company focuses on creating the next generation of antibiotics with innovative mechanisms of action. In addition to its drug development efforts, Oppilotech has established a computational modeling platform that utilizes systems biology and machine learning. This platform provides insights into biological processes at the cellular level, allowing for the accurate identification of viable drug targets. By simulating these biological processes, Oppilotech aims to facilitate the discovery of new therapeutic approaches and advance the treatment of infectious diseases.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Absynth Biologics Limited is a biotechnology company focused on discovering and developing vaccines and antibodies aimed at preventing and treating bacterial infections. Founded in 2007 and based in Alderley Edge, United Kingdom, the company specializes in creating products that target harmful bacteria, including staphylococcus aureus, clostridium difficile, and streptococcus pyogenes. Absynth employs a unique platform to identify novel protein antigen targets that enhance the immune response. Its approach utilizes a dual-action mechanism, which combines direct antibacterial activity through antibody-mediated effects with the activation of classic immune functions to combat bacterial pathogens. This strategy aims to improve patient immunity and address significant health threats posed by these infections.

Heartfelt Technologies Ltd. is a company based in Cambridge, United Kingdom, founded in 2015. It specializes in the development of an innovative in-home heart monitoring device designed to assist patients with congestive heart failure. The device features an optical sensor that automatically tracks the foot volume of patients as they walk past the monitor, capturing vital cardiovascular information in real-time. This data is processed through a cloud platform that alerts healthcare professionals when a patient shows signs of potential heart failure, thereby facilitating timely intervention. Heartfelt Technologies aims to reduce hospital re-admission rates associated with heart failure by empowering patients, their families, and caregivers with effective remote monitoring solutions.

Talisman Therapeutics Ltd is a research and development company based in Cambridge, United Kingdom, specializing in human stem cell drug discovery for the treatment of dementia, particularly Alzheimer's disease. Founded in 2013, the company utilizes innovative human stem cell models to create a platform that accelerates the identification and validation of potential drug compounds. Talisman's primary objective is to discover novel pharmacological treatments that address the initiation and progression of Alzheimer's disease through its in-house drug discovery program. In addition to its internal efforts, Talisman collaborates with large pharmaceutical companies, small biotech firms, and universities to enhance research and development activities in the field of neurodegenerative diseases.